Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
44
Recruiting, any sponsor type, condition "attention deficit hyperactivity disorder"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed552
44 trials
Showing 1 to 25, recently updated first.
VA Office of Research and DevelopmentFederal agency
NCT05776056 · 70 participants (planned) · Start Feb 5, 2024 · Primary completion Mar 31, 2027
Drug: Methylphenidate; Placebo · For: Posttraumatic Stress Disorder (PTSD)
Sites: Birmingham, Alabama; Tuscaloosa, Alabama; Seattle, Washington
- A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)Pivotal-lookingRecruiting
Alkermes, Inc.Industry
NCT07755410 · 312 participants (planned) · Start Aug 10, 2026 · Primary completion Jul 2027
Drug: ALKS 7290; Placebo · For: Attention Deficit Disorder With Hyperactivity (ADHD)
Sites: Little Rock, Arkansas; Chino, California; Clermont, Florida · 28 sites in all
- Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)Pivotal-lookingRecruiting
Axsome Therapeutics, Inc.Industry
NCT07717892 · 468 participants (planned) · Start Jun 25, 2026 · Primary completion Jun 30, 2028
Drug: Solriamfetol Dose A; Solriamfetol Dose B and 1 more · For: ADHD
Sites: Dothan, Alabama; Little Rock, Arkansas; Anaheim, California · 31 sites in all
- A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional DysregulationPivotal-lookingRecruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT07759154 · 80 participants (planned) · Start Sep 1, 2026 · Primary completion May 27, 2027
Drug: Centanafadine XR · For: Attention-deficit/Hyperactivity Disorder; Emotional Dysregulation
Sites: Gainesville, Florida; Jacksonville, Florida; Maitland, Florida · 16 sites in all
- Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)Pivotal-lookingRecruiting
Axsome Therapeutics, Inc.Industry
NCT07717879 · 468 participants (planned) · Start Jul 6, 2026 · Primary completion Jun 30, 2028
Drug: Solriamfetol Dose A; Solriamfetol Dose B and 1 more · For: ADHD
Sites: Dothan, Alabama; Little Rock, Arkansas; Anaheim, California · 32 sites in all
The Third Affiliated Hospital of Beijing University of Chinese MedicineAcademic, hospital or other
NCT06860763 · 120 participants (planned) · Start Oct 15, 2024 · Primary completion Dec 15, 2026
Drug: Chinese herbal medicine · For: Acupuncture; ADHD - Attention Deficit Disorder With Hyperactivity; Children and 3 more
Sites: Beijing, China
National Taiwan University HospitalAcademic, hospital or other
NCT07900451 · 90 participants (planned) · Start Aug 1, 2026 · Primary completion Jul 31, 2029
Drug: methylphenidate · For: ADHD
Sites: Taipei, Taiwan
- A Long-term Trial of EB-1020 in Adult Patients With ADHDPivotal-lookingRecruiting
Otsuka Pharmaceutical Co., Ltd.Otsuka
NCT06926829 · 180 participants (planned) · Start Jun 25, 2025 · Primary completion Dec 2027
Drug: EB-1020 (Centanafadine) 164.4 mg; EB-1020 (Centanafadine) 328.8 mg · For: Attention Deficit Hyperactivity Disorder (ADHD)
Sites: Tokyo, Japan
- Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD PatientsPivotal-lookingRecruiting
Otsuka Pharmaceutical Co., Ltd.Otsuka
NCT06931080 · 630 participants (planned) · Start Apr 30, 2025 · Primary completion Dec 2027
Drug: EB-1020 (Centanafadine) 164.4 mg; EB-1020 (Centanafadine) 328.8 mg and 1 more · For: Attention Deficit Hyperactivity Disorder (ADHD)
Sites: Tokyo, Japan
- AWARE: Management of ADHD in Autism Spectrum DisorderPivotal-lookingRecruiting
Daniel CouryAcademic, hospital or other
NCT05916339 · 500 participants (planned) · Start Oct 1, 2023 · Primary completion Jan 1, 2027
Drug: Randomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medication; Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant. · For: ADHD; Autism Spectrum Disorder
Sites: Irvine, California; Los Angeles, California; Portland, Maine · 13 sites in all
Dar Clinical Research Inc.Research network
NCT07710014 · 36 participants (planned) · Start Oct 6, 2026 · Primary completion Jul 21, 2027
Drug: Methylphenidate hydrochloride extended-release capsules · For: Attention Deficit Hyperactivity Disorder
Sites: Ottawa, Canada
- Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHDPivotal-lookingRecruiting
Supernus Pharmaceuticals, Inc.Industry
NCT04781140 · 286 participants (planned) · Start Mar 19, 2024 · Primary completion Jan 2028
Drug: 100mg SPN-812; Placebo · For: Attention-Deficit/Hyperactivity Disorder
Sites: Saraland, Alabama; Fayetteville, Arkansas; Little Rock, Arkansas · 54 sites in all
- Clinical Trial to Investigate the Safety and Efficacy of Two Dexamfetamine Sulfate Formulations in Adults With ADHD and Moderate to Severe DepressionPivotal-lookingRecruiting
Prof. Dr. Frank BehrensAcademic, hospital or other
NCT06967857 · 105 participants (planned) · Start May 15, 2025 · Primary completion Mar 2028
Drug: DEX IR tablets; DEX XL and 1 more · For: Attention-Deficit/Hyperactivity Disorder (ADHD); Depression - Major Depressive Disorder
Sites: Berlin, Germany; Bonn, Germany; Frankfurt, Germany · 5 sites in all
- Biomarker Validation in Motor System Physiology in Attention Deficit Hyperactivity DisorderPivotal-lookingRecruiting
Donald Gilbert, MD, MS, FAAN, FAAPAcademic, hospital or other
NCT04421248 · 214 participants (planned) · Start Sep 1, 2020 · Primary completion Feb 9, 2026
Drug: Methylphenidate; Placebo · For: Attention Deficit Hyperactivity Disorder Combined
Sites: Baltimore, Maryland; Cincinnati, Ohio
National Institute of Mental Health (NIMH)NIH
NCT00025935 · 2,350 participants (planned) · Start Jan 1, 2002
Drug: Lithium · For: Mood Disorder
Sites: Bethesda, Maryland
- Benefits of ADHD Treatment in Detained PeoplePivotal-lookingRecruiting
Stéphanie BaggioAcademic, hospital or other
NCT05842330 · 150 participants (planned) · Start Jan 1, 2024 · Primary completion Oct 30, 2026
Drug: Concerta; Placebo · For: ADHD
Sites: Geneva, Switzerland
The Second Hospital of Nanjing Medical UniversityAcademic, hospital or other
NCT06376331 · 50 participants (planned) · Start Apr 28, 2024 · Primary completion Jun 1, 2027
Drug: washed microbiota transplantation · For: Attention-deficit/Hyperactivity Disorder
Sites: Nanjing, China · 2 sites in all
- Treating Young Children With Attention Deficit Hyperactivity DisorderPivotal-lookingRecruiting
Children's Hospital Medical Center, CincinnatiAcademic, hospital or other
NCT07300956 · 370 participants (planned) · Start Feb 16, 2026 · Primary completion Feb 2030
Drug: Guanfacine (GUA); Methylphenidate (MPH) · For: Attention-Deficit/Hyperactivity Disorder (ADHD)
Sites: Palo Alto, California; Boston, Massachusetts; Kansas City, Missouri · 5 sites in all
- Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell DiseaseRecruiting
St. Jude Children's Research HospitalAcademic, hospital or other
NCT07226219 · 72 participants (planned) · Start Nov 25, 2025 · Primary completion Jul 1, 2027
Drug: Extended-Release Methylphenidate · For: Sickle Cell Disease; Executive Dysfunction; Cognitive Impairment and 1 more
Sites: Memphis, Tennessee
- EEG-MRI Imaging of Methylphenidate Effects in Adult ADHD and Attentional Symptoms in Mood DisordersPivotal-lookingRecruiting
University Hospital, Strasbourg, FranceAcademic, hospital or other
NCT05832489 · 80 participants (planned) · Start Feb 26, 2024 · Primary completion May 2027
Drug: Placebo; Methylphenidate immediate release 25mg · For: Adult ADHD; Adult-onset ADHD With Mood Disorder
Sites: Strasbourg, France
Duke UniversityAcademic, hospital or other
NCT04278404 · 5,000 participants (planned) · Start Mar 5, 2020 · Primary completion Nov 2026
Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: · For: Coronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children and 22 more
Sites: Phoenix, Arizona; Little Rock, Arkansas; Los Angeles, California · 52 sites in all
University of HaifaAcademic, hospital or other
NCT05133804 · 53 participants (planned) · Start Jun 1, 2022 · Primary completion Oct 1, 2026
Drug: Methylphenidate; Reboxetine and 2 more · For: Posttraumatic Stress Disorder
Sites: Afula, Israel; Haifa, Israel; Netanya, Israel
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.Academic, hospital or other
NCT07594652 · 25 participants (planned) · Start May 29, 2026 · Primary completion Dec 2030
Drug: methylphenidate hydrochloride (Jornay PM) · For: ADHD - Attention Deficit Disorder With Hyperactivity
Sites: Baltimore, Maryland
- Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental DisordersPivotal-lookingRecruiting
Holland Bloorview Kids Rehabilitation HospitalAcademic, hospital or other
NCT06081348 · 130 participants (planned) · Start Sep 16, 2024 · Primary completion Sep 2027
Drug: Sertraline · For: Neurodevelopmental Disorders; Autism; Autism Spectrum Disorder and 14 more
Sites: Calgary, Canada; Edmonton, Canada; Halifax, Canada · 7 sites in all
- Atomoxetine and Executive Function in PTSDPivotal-lookingRecruiting
VA Office of Research and DevelopmentFederal agency
NCT06573970 · 160 participants (planned) · Start Apr 1, 2026 · Primary completion Jun 29, 2029
Drug: Atomoxetine; Placebo · For: Posttraumatic Stress Disorder With Attention Defic
Sites: Charleston, South Carolina
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.